Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases in patients with a low clinical risk score – a randomized controlled trial

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512850-10-00

Enrollment

230

Registered

2024-10-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Resectable colorectal rectal metastases without extrahepatic disease

Brief summary

progression free survival (PFS)

Detailed description

Overall survival, Progression free survival in the liver, Postoperative complications, adverse events, Quality of life, Cost effectiveness, the accuracy of CT angiography to detect extrahepatic perfusion, pharmacokinetic profile of intra-arterial administration of floxuridine will, predictive biomarkers for the efficacy of HAIP chemotherapy

Interventions

DRUG-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
progression free survival (PFS)	—

Secondary

Measure	Time frame
Overall survival, Progression free survival in the liver, Postoperative complications, adverse events, Quality of life, Cost effectiveness, the accuracy of CT angiography to detect extrahepatic perfusion, pharmacokinetic profile of intra-arterial administration of floxuridine will, predictive biomarkers for the efficacy of HAIP chemotherapy	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026